Product Vigilance Advisory Committee
Term
1 August 2023 - 31 July 2026
Scope
The Product Vigilance Advisory Committee (PVAC) provides scientific advice to HPRG in relation to the continued availability and safe use of health products in Singapore, through the following:
- To review the benefit-risk profile of health products, assess the impact of significant safety issues associated with health products and advise on the appropriate regulatory actions to be taken to minimise the risk associated with the use of these products.
- To review serious selected adverse event reports, and advise on the causality assessment and appropriate follow-up actions to be initiated by HSA.
- To provide guidance on innovative post-marketing surveillance tools.
- To be an advocate of health products vigilance and actively promote adverse event reporting by healthcare professionals.
- To contribute to HSA’s educational programmes on health product safety in Singapore.
Committee members
- Prof Goh Chee Leok (Chairman)
- Assoc Prof Sum Chee Fang (Deputy Chairman)
- Ms Jalene Poh (Secretary)
- Assoc Prof Jason Choo
- Assoc Prof Chow Wan Cheng
- Assoc Prof Ding Zee Pin
- Prof Derrick Heng
- Dr Belinda Lee
- Emeritus Prof Edmund Lee
- Dr Shen Liang
- Dr Tan Lip Kun
- Clinical Prof Tan Thuan Tong
- Adj Assoc Prof Tan Tze Lee
- Adj Assoc Prof Bernard Thong
- Dr Camilla Wong